167 related articles for article (PubMed ID: 2166154)
21. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide-induced hyperpigmentation.
Teresi ME; Murry DJ; Cornelius AS
Cancer; 1993 May; 71(9):2873-5. PubMed ID: 8385568
[TBL] [Abstract][Full Text] [Related]
23. Ifosfamide-induced Fanconi syndrome.
Garcia AA
Ann Pharmacother; 1995 Jun; 29(6):590-1. PubMed ID: 7663031
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide induced Fanconi syndrome.
Buttemer S; Pai M; Lau KK
BMJ Case Rep; 2011 Dec; 2011():. PubMed ID: 22669992
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child.
De Schepper J; Stevens G; Verboven M; Baeta C; Otten J
Am J Pediatr Hematol Oncol; 1991; 13(1):39-41. PubMed ID: 2029077
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for ifosfamide nephrotoxicity in children.
Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
[TBL] [Abstract][Full Text] [Related]
27. Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology.
Tournade MF; Lemerle J; Brunat-Mentigny M; Bachelot C; Roche H; Taboureau O; Olive D; Lejars O; Boilletot A; Demeocq F
J Clin Oncol; 1988 May; 6(5):793-6. PubMed ID: 2835442
[TBL] [Abstract][Full Text] [Related]
28. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
29. Hypophosphataemic rickets after ifosfamide treatment in children.
Sweeney LE
Clin Radiol; 1993 May; 47(5):345-7. PubMed ID: 8508598
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
Tournade MF
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S31-3. PubMed ID: 2547529
[TBL] [Abstract][Full Text] [Related]
31. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
32. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Jones DP; Chesney RW
Curr Opin Pediatr; 1995 Apr; 7(2):208-13. PubMed ID: 7787938
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
Phillips RS; Tyerman K; Al-Kassim MI; Picton S
Pediatr Hematol Oncol; 2008 Mar; 25(2):107-13. PubMed ID: 18363176
[TBL] [Abstract][Full Text] [Related]
34. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Leem AY; Kim HS; Yoo BW; Kang BD; Kim MH; Rha SY; Kim HS
Korean J Intern Med; 2014 Mar; 29(2):246-9. PubMed ID: 24648810
[TBL] [Abstract][Full Text] [Related]
36. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
37. Concentrating capacity in ifosfamide-induced severe renal dysfunction.
Rossi R; Gödde A; Kleinebrand A; Rath B; Jürgens H
Ren Fail; 1995 Sep; 17(5):551-7. PubMed ID: 8570867
[TBL] [Abstract][Full Text] [Related]
38. A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.
Hoang S; Pujar T; Bellorin-Font E; Edwards JC; Miyata KN
CEN Case Rep; 2024 Jun; 13(3):194-198. PubMed ID: 37897631
[TBL] [Abstract][Full Text] [Related]
39. Refining therapeutic strategies for patients with resistant Wilm's tumor.
Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
[TBL] [Abstract][Full Text] [Related]
40. Progressive renal toxicity due to ifosfamide.
Heney D; Wheeldon J; Rushworth P; Chapman C; Lewis IJ; Bailey CC
Arch Dis Child; 1991 Aug; 66(8):966-70. PubMed ID: 1718222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
